Clopidogrel tablets for reducing heart attack and stroke risk in acute coronary syndrome and vascular disease

Clopidogrel is an oral antiplatelet medication used to reduce the risk of heart attack and stroke in patients with acute coronary syndrome (ACS), recent heart attack or stroke, or established peripheral arterial disease. It works by preventing blood cells called platelets from clumping together and forming clots.

Clopidogrel is prescribed for the following conditions:

• Acute coronary syndrome (ACS): To reduce the risk of myocardial infarction (MI) and stroke in patients with non–ST-segment elevation ACS (unstable angina or NSTEMI), including those managed medically or with coronary revascularization. Clopidogrel should be used together with aspirin.
• ST-elevation myocardial infarction (STEMI): To reduce MI and stroke rates in patients treated medically, also alongside aspirin.
• Recent MI, recent stroke, or established peripheral arterial disease: To lower the risk of subsequent MI and stroke.

Clopidogrel bisulfate

Clopidogrel is a prodrug that requires conversion by the liver enzyme CYP2C19 into an active form. This active metabolite blocks the P2Y12 receptor on platelets, inhibiting their ability to clump together and form blood clots. This reduction in platelet aggregation helps prevent the blockage of blood vessels that can cause heart attacks and strokes.

Because genetic variations or certain drugs can reduce CYP2C19 activity, clopidogrel’s effectiveness may be diminished in some patients.

Acute coronary syndrome: Start with a 300 mg oral loading dose followed by 75 mg once daily. Starting without the loading dose delays the antiplatelet effect by several days.

Recent MI, stroke, or peripheral arterial disease: 75 mg once daily orally without a loading dose.

• Active pathological bleeding such as peptic ulcer or intracranial hemorrhage.
• Hypersensitivity to clopidogrel or any component of the product (e.g., anaphylaxis).

• Diminished effect in CYP2C19 poor metabolizers: Patients with two nonfunctional CYP2C19 alleles have reduced conversion to the active metabolite, lowering clopidogrel’s effectiveness. Alternative platelet P2Y12 inhibitors should be considered in these patients.
• Bleeding risk: Clopidogrel increases bleeding risk, including serious and fatal bleeding. Platelet aggregation inhibition lasts 7–10 days. Use caution with other drugs that increase bleeding risk (anticoagulants, antiplatelets, NSAIDs). Avoid platelet transfusion within 4 hours of loading dose or 2 hours of maintenance dose as it may be less effective.
• Drug interactions: Avoid concomitant use with CYP2C19 inhibitors such as omeprazole or esomeprazole as they reduce clopidogrel’s antiplatelet activity. Strong CYP2C19 inducers may increase bleeding risk.
• Discontinuation: Stopping clopidogrel increases cardiovascular event risk. If discontinued temporarily (e.g., for surgery), resume as soon as bleeding risk is controlled. Stop 5 days before elective surgery with major bleeding risk.
• Thrombotic thrombocytopenic purpura (TTP): A rare but serious condition occurring sometimes within 2 weeks of starting, characterized by low platelets, hemolytic anemia, neurological symptoms, kidney dysfunction, and fever. Requires urgent treatment.
• Hypersensitivity: Allergic reactions (rash, angioedema) can occur, especially in patients with prior reactions to similar drugs.

Common adverse reactions: Bleeding is the most frequent side effect, ranging from minor bruising and nosebleeds to major gastrointestinal bleeding. In clinical studies, major bleeding risk was increased when clopidogrel was combined with aspirin compared to aspirin alone.

Serious reactions: Thrombotic thrombocytopenic purpura (TTP) has been reported. Postmarketing reports include hematologic disorders such as agranulocytosis and aplastic anemia; gastrointestinal issues including ulcers and colitis; liver function abnormalities; allergic reactions; skin reactions; and respiratory disorders.

• CYP2C19 inhibitors (omeprazole, esomeprazole): Reduce the formation of clopidogrel's active metabolite, decreasing its effectiveness. Avoid concomitant use.
• Strong CYP2C19 inducers: May increase active metabolite levels and bleeding risk; avoid if possible.
• Other bleeding risk drugs: Concomitant use with anticoagulants, antiplatelet agents, or chronic NSAIDs increases bleeding risk.